<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396837</url>
  </required_header>
  <id_info>
    <org_study_id>RD003</org_study_id>
    <nct_id>NCT01396837</nct_id>
  </id_info>
  <brief_title>Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.</brief_title>
  <official_title>A Multi-Center, Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedDress Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedDress Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of the RedDress Wound Care System (RD1) in&#xD;
      patients Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational product, the RD1 kit, was designed to enable a care provider to create an&#xD;
      in vitro blood clot from the patient's own blood at the point of care, in a safe and&#xD;
      effective manner.&#xD;
&#xD;
      While many advanced modalities of treatment have been developed to heal chronic DFUs (as well&#xD;
      as other types of chronic wounds), the vast majority have been approved for relatively&#xD;
      non-severe wounds (e.g., Texas 1a/2a grades) and relatively healthy subjects in controlled&#xD;
      clinical trials and typically exclude 25-75% of subjects who have several comorbidities and&#xD;
      severe wounds. Moreover, when the results of such trials (and other trials of advanced&#xD;
      modalities) have been subject to a systematic review, the strength of the evidence for their&#xD;
      efficacy has been rated low or even insufficient to judge. Consequently, there is an urgent&#xD;
      need for new technologies to be tested that can improve healing rates in all classes of&#xD;
      chronic DFUs.&#xD;
&#xD;
      The study is a multi-center, prospective, single group safety study, consisting of 20&#xD;
      subjects who will complete the study (note: if any patients are lost to follow-up or&#xD;
      withdrawn, enrollment will increase to compensate for loss of these subjects). The subjects&#xD;
      will receive 12 weekly RD1 applications. Subject data will be kept in each site's records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Autologous Blood Clot Product was applied to all patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse event rate will be calculated including serious adverse events (SAEs), adverse events (AEs) (including any lack of venous access events), and device-related adverse events (DRAEs) (safety population and ITT populations).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experience Complications Due to Lack of Venous Access</measure>
    <time_frame>12 weeks</time_frame>
    <description>For all patients for all 12 visits involving RD1 procedure (ITT population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Complete Wound Closure at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart) for DFU treated with RD1 (ITT population).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Reduction in Wound Size Over 12 Weeks (ITT Population)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The data will also be plotted graphically week by week. Week 12 data will be used to recalculate sample size for the pivotal trial</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Neuropathic Diabetic Ulcer - Foot</condition>
  <arm_group>
    <arm_group_label>RedDress Wound Care System (RD1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RedDress Wound Care System (RD1)</intervention_name>
    <description>Weekly application. A blood based wound care treatment</description>
    <arm_group_label>RedDress Wound Care System (RD1)</arm_group_label>
    <other_name>RedDress Wound Care System</other_name>
    <other_name>RD1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is ≥18 years of age and has type 1 or 2 diabetes&#xD;
&#xD;
          -  Texas grade 1a or 2a wound located distal to the malleolus (excluding ulcers between&#xD;
             the toes but including those of the heel) and depth ≤ 5 mm with no exposed capsule,&#xD;
             tendon or bone and no tunneling, undermining or sinus tracts&#xD;
&#xD;
          -  Prior to inclusion of an ulcer in the study, each wound will be reviewed for&#xD;
             eligibility by an independent assessor using a central online review process that&#xD;
             includes images of the ulcer.&#xD;
&#xD;
          -  For patients with potentially multiple eligible DFUs, the biggest ulcer will be chosen&#xD;
             as the study ulcer.&#xD;
&#xD;
          -  Ulcer size between 1 cm2 and 12 cm2 (post-debridement).&#xD;
&#xD;
          -  Ulcer duration of ≥ 30 days. Time 0 for ulcer duration of ≥ 30 days is defined as the&#xD;
             first day of screening (i.e., day -14). Subjects will need to meet all inclusion&#xD;
             criteria, including lack of ulcer healing until day 0.&#xD;
&#xD;
          -  Study ulcer separated from other ulcers by at least 2 cm.&#xD;
&#xD;
          -  Ulcer or affected limb free of clinical signs of infection. (Subjects with wound&#xD;
             infection at the screening visit may be treated and re-screened for participation in&#xD;
             the study after eradication of the infection).&#xD;
&#xD;
          -  Post-debridement, ulcer free of necrotic tissue.&#xD;
&#xD;
          -  Subject has adequate vascular perfusion of the affected limb, as defined by at least&#xD;
             one of the following: (a) Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.2; (b) toe&#xD;
             pressure (plethysmography) &gt; 50 mm Hg; (c) TcPO2 &gt; 40 mm Hg; or (d) skin perfusion&#xD;
             pressure (SPP) &gt; 30 mm Hg.&#xD;
&#xD;
          -  HbA1c ≤ 12.0% (diabetic patients)&#xD;
&#xD;
          -  Demonstrated adequate offloading regimen.&#xD;
&#xD;
          -  Subject must be willing to comply with the protocol including having blood drawn to&#xD;
             create the RD1.&#xD;
&#xD;
          -  Female subjects who are capable of conceiving and all males capable of insemination&#xD;
             must use an acceptable form of contraception in order to participate in the study&#xD;
             (acceptable forms of contraception include condoms for males and contraceptive pills&#xD;
             or IUDs for women).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ulcer not of neuropathic diabetic foot pathophysiology (e.g., venous, vasculitic,&#xD;
             radiation, rheumatoid, collagen vascular disease, or arterial etiology, or pressure&#xD;
             ulcers.).&#xD;
&#xD;
          -  Presence of underlying osteomyelitis.&#xD;
&#xD;
          -  Patient with a proven sepsis established by a blood culture in the past 2 weeks, or&#xD;
             confirmed active infection likely to interfere with trial, such as urine tract&#xD;
             infection.&#xD;
&#xD;
          -  History of alcohol or substance abuse, within the previous 2 months&#xD;
&#xD;
          -  Subject has participated in another clinical trial involving a device or a&#xD;
             systemically administered investigational study drug or treatment within 30 days of&#xD;
             randomization visit.&#xD;
&#xD;
          -  Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive&#xD;
             a medication or treatment which, in the opinion of the Investigator, is known to&#xD;
             interfere with, or affect the rate and quality of, wound healing (e.g., systemic&#xD;
             steroids, immunosuppressive therapy, autoimmune disease therapy, cytostatic therapy&#xD;
             within the past 12 months, dialysis, radiation therapy to the foot, vascular surgery,&#xD;
             angioplasty or thrombolysis).&#xD;
&#xD;
          -  Subject has been treated with wound dressings that include growth factors, engineered&#xD;
             tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, GraftJacket®,&#xD;
             OASIS®, Primatrix®, Matristem®, etc.) within 30 days of randomization or is scheduled&#xD;
             to receive during the study.&#xD;
&#xD;
          -  Subject has been treated with hyperbaric oxygen within 5 days of screening or is&#xD;
             scheduled to receive during the study.&#xD;
&#xD;
          -  Wound on a patient who has a life expectancy of less than 12 months.&#xD;
&#xD;
          -  Subjects who are cognitively impaired and have a healthcare proxy or those who are&#xD;
             cognitively impaired and clearly do not understand the contents of the informed&#xD;
             consent form.&#xD;
&#xD;
          -  Cannot withdraw blood in the required amount (up to 10 mL per week) technically.&#xD;
&#xD;
          -  Known coagulation problems, abnormal thrombocytes level or if heparin is given&#xD;
             intravenously. Patients who are taking coumadin, aspirin, or Plavix (clopidogrel) will&#xD;
             not be excluded.&#xD;
&#xD;
          -  Hemoglobin anemia (&lt; 10 g/dL).&#xD;
&#xD;
          -  Subject has a history of or any of the following intercurrent illnesses or conditions&#xD;
             that would compromise the safety of the subject, or the normal wound healing process:&#xD;
&#xD;
               -  End stage renal disease&#xD;
&#xD;
               -  Immunosuppression.&#xD;
&#xD;
               -  Severe malnutrition&#xD;
&#xD;
               -  Liver disease&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Acquired immune deficiency disease (AIDS) or HIV positive&#xD;
&#xD;
               -  Connective tissue disorder&#xD;
&#xD;
               -  Exacerbation of sickle cell anemia&#xD;
&#xD;
          -  If ulcer area decreases by ≥ 30% during the initial 2-week screening (± 2 days) and&#xD;
             standard of care phase, or if the ulcer area increases ≥ 30%, subject will be&#xD;
             excluded.&#xD;
&#xD;
          -  Women who are pregnant or currently breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amun Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barry University Clinical Research</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SerenaGroup Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <results_first_submitted>October 22, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>Diabetic Ulcer</keyword>
  <keyword>Diabetic Wound</keyword>
  <keyword>Chronic Ulcer</keyword>
  <keyword>Chronic Wound</keyword>
  <keyword>Neuropathic Diabetic Foot Ulcer</keyword>
  <keyword>Neuropathic DFU</keyword>
  <keyword>DFU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RedDress Wound Care System (RD1)</title>
          <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RedDress Wound Care System (RD1)</title>
          <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;18 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events</title>
        <description>Adverse event rate will be calculated including serious adverse events (SAEs), adverse events (AEs) (including any lack of venous access events), and device-related adverse events (DRAEs) (safety population and ITT populations).</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>RedDress Wound Care System (RD1)</title>
            <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events</title>
          <description>Adverse event rate will be calculated including serious adverse events (SAEs), adverse events (AEs) (including any lack of venous access events), and device-related adverse events (DRAEs) (safety population and ITT populations).</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experience Complications Due to Lack of Venous Access</title>
        <description>For all patients for all 12 visits involving RD1 procedure (ITT population)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RedDress Wound Care System (RD1)</title>
            <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experience Complications Due to Lack of Venous Access</title>
          <description>For all patients for all 12 visits involving RD1 procedure (ITT population)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Complete Wound Closure at 12 Weeks</title>
        <description>Defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart) for DFU treated with RD1 (ITT population).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RedDress Wound Care System (RD1)</title>
            <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Complete Wound Closure at 12 Weeks</title>
          <description>Defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart) for DFU treated with RD1 (ITT population).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Reduction in Wound Size Over 12 Weeks (ITT Population)</title>
        <description>The data will also be plotted graphically week by week. Week 12 data will be used to recalculate sample size for the pivotal trial</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RedDress Wound Care System (RD1)</title>
            <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Reduction in Wound Size Over 12 Weeks (ITT Population)</title>
          <description>The data will also be plotted graphically week by week. Week 12 data will be used to recalculate sample size for the pivotal trial</description>
          <units>percentage of area reduction</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" lower_limit="34.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were followed for 12 weeks</time_frame>
      <desc>The NCI CTCAEv5 scale was used to grade adverse events/serious adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>RedDress Wound Care System (RD1)</title>
          <description>RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit&#xD;
RedDress Wound Care System (RD1): Weekly application. A blood based wound care treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection,</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal problem</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Prophylactic use antibiotics</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection, other wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection, study DFU</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain at study ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Friction blister at study ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Friction blister, other wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Traumatic injury (not study wound)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Traumatic injury (study wound)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>New DFU</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Restless leg syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sudden increase area study ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saron Sirota, Clinical Team Leader</name_or_title>
      <organization>RedDress</organization>
      <phone>+972-54-5800765</phone>
      <email>sharon@reddress.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

